Arcus Biosciences Inc (RCUS) - News Archive

In the fast-evolving landscape of biopharmaceutical innovation, Arcus Biosciences, Inc. (NYSE:RCUS) stands at the forefront, dedicated to shaping the future of cancer treatment with its advanced therapeutic strategies a...

Arcus Biosciences and Taiho Pharmaceutical Forge Strategic Partnership for Casdatifan Licensing Across Asia In a bold move that underscores the growing collaboration between global biopharmaceutical entities, Taiho Phar...

Arcus Biosciences: A Promising Leap in Oncology Treatments and Employer IncentivesNew Employment Inducements and Breakthroughs in Cancer Therapy Show Growth Trajectory In a series of significant announcements, Arcus Bio...

Arcus Biosciences Fortifies Oncology Pipeline and Financial Position with Strategic Moves Arcus Biosciences, Inc. (NYSE:RCUS), a trailblazing entity in the sphere of clinical-stage global biopharmaceutical research, rec...

At the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Arcus Biosciences, Inc. (NYSE: RCUS) unveiled promising new data for its lead investigational drug, casdatifan, a hypoxia-in...

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Pipeline Momentum in Cancer Therapies HAYWARD, Calif. In a recent announcement, Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical...

Hayward, Calif. - Arcus Biosciences, Inc. (NYSE: RCUS), a pioneering clinical-stage biopharmaceutical company committed to combating cancer with innovative molecules and combination therapies, has released its financial...

In a significant development for the treatment of non-small cell lung cancer (NSCLC), Arcus Biosciences, Inc. (NYSE: RCUS) has announced that its combination therapy, featuring Domvanalimab and Zimberelimab, has demonst...

Harnessing Innovation in Oncology: Arcus Biosciences Poised to Unveil Pioneering ARC-20 Study Data at the 2024 EORTC-NCI-AACR Symposium HAYWARD, Calif. A beacon of innovative cancer research, Arcus Biosciences, Inc. (NY...

Arcus Biosciences, Inc. a clinical-stage biopharmaceutical company, is gaining traction in the cancer treatment landscape through strategic collaborations and innovative therapies. This article examines significant rece...

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE: RCUS), a leading clinical-stage global biopharmaceutical company, has announced a pivotal clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN). T...

In a significant development within the pharmaceutical landscape, Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (Taiho) have jointly announced that Taiho has exercised its option for an exclusiv...

In a groundbreaking development, Arcus Biosciences, a leading global biopharmaceutical company, has recently announced the successful completion of patient enrollment for STAR-221, a crucial Phase 3 clinical trial in co...

Arcus Biosciences Reports Strong Financial Results and Promising Pipeline Update for Q1 2024Hayward, Calif. - Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical company dedicated to developing inno...

Arcus Biosciences (NYSE: RCUS), a renowned clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment through the development of innovative molecules and combination therapies, recently held...

Combining s:Arcus Biosciences, a renowned clinical-stage biopharmaceutical company based in Hayward, California, is set to host a highly anticipated conference call and webcast on May 8th, 2024. This event will provide...

Arcus Biosciences, a leading global biopharmaceutical company focused on cancer therapeutics, has recently granted options to four new employees to purchase a total of 18,400 shares of the company s common stock. The ex...

Arcus Biosciences Empowers Cancer Therapies Development with New Employment Inducement GrantsArcus Biosciences, Inc. recently announced the granting of options to purchase a total of 17,600 shares of the company s commo...

Arcus Biosciences Announces New Employment Inducement Grants to Support Cancer Research and DevelopmentHayward, Calif. - Arcus Biosciences, a leading global biopharmaceutical company dedicated to developing impactful mo...

Gilead Sciences, Inc. and Arcus Biosciences, Inc. have recently announced an amendment to their collaboration agreement, along with a significant equity investment by Gilead. The amendment and investment aim to accelera...